Kinetic analysis of saturable hepatic uptake of digoxin and its inhibition by rifampicin

European Journal of Pharmaceutical Sciences

Volumn 34, Issue 4-5, 2008, Pages 345-350

  Weiss, Michael ^a   Hung, Daniel Y ^b   Poenicke, Klaus ^a   Roberts, Michael S ^b  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Digoxin; Hepatic uptake; Oatp2; Rat liver; Rifampicin

Indexed keywords

DIGOXIN; ORGANIC ANION TRANSPORTER 2; RIFAMPICIN;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG LIVER LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIVER PERFUSION; MALE; MICHAELIS MENTEN KINETICS; NONHUMAN; NONLINEAR REGRESSION ANALYSIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; SIMULATION;

ANIMALS; DIGOXIN; KINETICS; LIVER; MALE; MODELS, BIOLOGICAL; ORGANIC ANION TRANSPORTERS; PERFUSION; RATS; RATS, WISTAR; RIFAMPIN;

EID: 79955668560     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2008.05.007     Document Type: Article

References (25)

1. Cheung K., Hickman P.E., Potter J.M., Walker N., Jericho M., Haslam R., and Roberts M.S. An optimised model for rat liver perfusion studies. J. Surg. Res. 66 (1996) 81-89
2. D'Argenio D.Z., and Schumitzky A. ADAPT II User's Guide: Pharmacokinetic/Pharmacodynamic Systems Analysis Software (1997), Biomedical Simulations Resource, Los Angeles
3. Embree L., and McErlane L. Development of a high-performance liquid chromatographic-post-column fluorogenic assay for digoxin in serum. J. Chromatogr. 496 (1989) 321-334
4. Faber K.N., Müller M., and Jansen P.L. Drug transport proteins in the liver. Adv. Drug Deliv. 55 (2003) 107-124
5. Fattinger K., Cattori V., Hagenbuch B., Meier P.J., and Stieger B. Rifamycin SV and rifampicin exhibit differential inhibition of the hepatic rat organic anion transporting polypeptides, Oatp1 and Oatp2. Hepatology 32 (2000) 82-86
6. Frasetto L.A., Poon S., Tsourounis C., Valera C., and Benet L.Z. Effects of uptake and efflux transporter inhibition on erythromycin breath test results. Clin. Pharmacol. Ther. 81 (2007) 828-832
7. Ito S., Nasu R., Tsujimoto M., Murakami H., Ohtani H., and Sawada Y. Effect of macrolide antibiotics on uptake of digoxin into rat liver. Biopharm. Drug Dispos. 28 (2007) 113-123
8. Kang W., and Weiss M. Digoxin uptake, receptor heterogeneity, and inotropic response in the isolated rat heart: A comprehensive kinetic model. J. Pharmacol. Exp. Ther. 302 (2002) 577-583
9. Kakkar T., Pak Y., and Mayersohn M. Evaluation of a minimal experimental design for determination of enzyme kinetic parameters and inhibition mechanism. J. Pharmacol. Exp. Ther. 293 (2000) 861-869
10. Kodawara T., Masuda S., Wakasugi H., Uwai Y., Futami T.T., Saito H., Abe T., and Inu K. Organic anion transporter oatp2-mediated interaction between digoxin and amiodarone in the rat liver. Pharm. Res. 19 (2002) 738-743
11. Lam J.L., and Benet L.Z. Hepatic microsome studies are insufficient to characterize in vivo hepatic metabolic clearance and metabolic drug-drug interactions: studies of digoxin metabolism in primary rat hepatocytes versus microsomes. Drug Metab. Dispos. 32 (2004) 1311-1316
12. Lam J.L., Okochi H., Huang Y., and Benet L.Z. In vitro and in vivo correlation of hepatic transporter effects on erythromycin metabolism: characterizing the importance of transporter-enzyme interplay. Drug Metab. Dispos. 34 (2006) 1336-1344
13. Lau Y.Y., Wu C.Y., Okochi H., and Benet L.Z. Ex situ inhibition of hepatic uptake and efflux significantly changes metabolism: hepatic enzyme-transporter interplay. J. Pharmacol. Exp. Ther. 308 (2004) 1040-1045
14. Liu L., and Pang K.S. An integrated approach to model hepatic drug clearance. Eur. J. Pharm. Sci. 29 (2006) 215-230
15. Liu L., Mak E., Tirona R.G., Tan E., Novikoff P.M., Wang P., Wolkoff A.W., and Pang K.S. Vascular binding, blood flow, transporter, and enzyme interactions on the processing of digoxin in rat liver. J. Pharmacol. Exp. Ther. 315 (2005) 433-448
16. Noé B., Hagenbuch B., Stieger B., and Meier P.J. Isolation of a multispecific organic anion and cardiac glycoside transporter from rat brain. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 10346-10350
17. Reichel C., Gao B., Van Montfoort J., Cattori V., Rahner C., Hagenbuch B., Stieger B., Kamisako T., and Meier P.J. Localization and function of the organic anion-transporting polypeptide Oatp2 in rat liver. Gastroenterology 117 (1999) 688-695
18. Salphati L., and Benet L.Z. Metabolism of digoxin and digoxigenin digitoxosides in rat liver microsomes: involvement of cytochrome P4503A. Xenobiotica 29 (1999) 171-185
19. Shitara Y., Itoh T., Sato H., Li A.P., and Sugiyama Y. Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J. Pharmacol. Exp. Ther. 304 (2003) 610-616
20. Shitara Y., Sato H., and Sugiyama Y. Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. Annu. Rev. Pharmacol. Toxicol. 45 (2005) 689-723
21. Sirianni G.L., and Pang K.S. Organ clearance concepts: new perspectives on old principles. J. Pharmacokinet. Biopharm. 25 (1997) 449-470
22. Treiber A., Schneiter R., Delahaye S., and Clozel M. Inhibition of organic anion transporting polypeptide-mediated hepatic uptake is the major determinant in the pharmacokinetic interaction between bosentan and cyclosporin A in the rat. J. Pharmacol. Exp. Ther. 308 (2004) 1121-1129
23. Webborn P.J.H., Parker A.J., Denton R.L., and Riley R.J. In vitro-in vivo extrapolation of hepatic clearance involving active uptake: Theoretical and experimental aspects. Xenobiotica 37 (2007) 1090-1109
24. Weiss M., Kuhlmann O., Hung D.Y., and Roberts M.S. Cytoplasmic binding and disposition kinetics of diclofenac in the isolated perfused rat liver. Br. J. Pharmacol. 130 (2000) 1331-1338
25. Wu C.Y., and Benet L.Z. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm. Res. 22 (2005) 11-23